阿贝西利联合氟维司群治疗CDK4/6抑制剂进展后的晚期乳腺癌:III期postMONARCH试验结果
postMONARCH是一项双盲随机III期试验,纳入368例既往CDK4/6抑制剂联合内分泌治疗进展的HR+/HER2-晚期乳腺癌患者,随机接受阿贝西利联合氟维司群或安慰剂联合氟维司群。主要终点研究者评估的无进展生存期(PFS)显著改善,风险比0.73(95%CI 0.57-0.95;名义P=0.017),中位PFS 6.0个月 vs 5.3个月,6个月PFS率50% vs 37%。
要点
- 阿贝西利联合氟维司群较安慰剂联合氟维司群显著改善PFS(HR 0.73;95%CI 0.57-0.95;名义P=0.017)。
- 中位PFS:阿贝西利联合氟维司群6.0个月 vs 安慰剂联合氟维司群5.3个月;6个月PFS率50% vs 37%。
- 客观缓解率:阿贝西利联合氟维司群17% vs 安慰剂联合氟维司群7%(名义P=0.015);安全性特征与已知一致。
核心结论
- 在既往CDK4/6抑制剂联合内分泌治疗进展的HR+/HER2-晚期乳腺癌患者中,阿贝西利联合氟维司群显著改善PFS,提供额外的靶向治疗选择。
研究设计与样本
- 双盲、随机、安慰剂对照III期试验(postMONARCH),纳入既往CDK4/6抑制剂联合芳香化酶抑制剂作为晚期初始治疗进展或辅助CDK4/6抑制剂联合内分泌治疗后复发的患者,随机1:1分配至阿贝西利联合氟维司群(n=182)或安慰剂联合氟维司群(n=186),共368例。
主要发现
- 主要分析(258例事件)时,研究者评估的PFS风险比HR 0.73(95%CI 0.57-0.95;名义P=0.017),中位PFS阿贝西利联合氟维司群6.0个月(95%CI 5.6-8.6)vs 安慰剂联合氟维司群5.3个月(95%CI 3.7-5.6),6个月PFS率分别为50%和37%。
- 盲态独立中心审查评估的PFS支持该结果(HR 0.55;95%CI 0.39-0.77;名义P<0.001)。
- 在可测量疾病患者中,研究者评估的客观缓解率阿贝西利联合氟维司群17% vs 安慰剂联合氟维司群7%(名义P=0.015)。
- 在主要临床和基因组亚组(包括伴或不伴ESR1或PIK3CA突变)中观察到一致的治疗效应。
- 未观察到新的安全性信号,结果与阿贝西利已知安全性特征一致。
关键数值与推荐
- 研究者评估的PFS风险比HR 0.73(95%CI 0.57-0.95;名义P=0.017),中位PFS 6.0个月(95%CI 5.6-8.6)vs 5.3个月(95%CI 3.7-5.6),6个月PFS率50% vs 37%。
- 盲态独立中心审查评估的PFS风险比HR 0.55(95%CI 0.39-0.77;名义P<0.001)。
- 可测量疾病患者中研究者评估的客观缓解率17% vs 7%(名义P=0.015)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC); however, disease progression occurs in almost all patients and additional treatment options are needed. Herein, we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i. METHODS: This double-blind, randomized phase III study enrolled patients with disease progression on previous CDK4/6i plus aromatase inhibitor as initial therapy for advanced disease or recurrence on/after adjuvant CDK4/6i + ET. Patients were randomly assigned (1:1) to abemaciclib + fulvestrant or placebo + fulvestrant. The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included PFS by blinded independent central review, objective response rate (ORR), and safety. RESULTS: This study randomly assigned 368 patients (abemaciclib + fulvestrant, n = 182 placebo + fulvestrant, n = 186). At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001). A consistent treatment effect was seen across major clinical and genomic subgroups, including with/without ESR1 or PIK3CA mutations. Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015). No new safety signals were observed, with findings consistent with the known safety profile of abemaciclib. CONCLUSION: Abemaciclib + fulvestrant significantly improved PFS after disease progression on previous CDK4/6i + ET in patients with HR+, HER2- ABC, offering an additional targeted therapy option for these patients.
引用
- Kalinsky K, Bianchini G, Hamilton E, et al. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2024. PMID: 39693591. doi:10.1200/JCO-24-02086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。